Core Insights - Company enters a global strategic partnership with Takeda Pharmaceuticals to accelerate the development of next-generation IO and ADC therapies, expanding global market value [1] - The collaboration includes late-stage therapies IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2ADC), as well as an early-stage project IBI3001 (EGFR/B7H3 ADC) [1] Group 1 - The partnership allows for joint development of IBI363 (PD-1/IL-2) globally, with Takeda leading the commercialization efforts in the U.S. [1] - Company grants Takeda commercialization rights for IBI363 outside Greater China and the U.S. [1] - Takeda receives exclusive rights for IBI343 (CLDN18.2ADC) outside Greater China and an exclusive option for IBI3001 (EGFR/B7H3 ADC) outside Greater China [1] Group 2 - Company will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million at a 20% premium to the weighted average closing price over the previous 30 trading days [2] - Potential milestone payments could total up to $10.2 billion, making the total transaction value up to $11.4 billion [2] - Company will also receive a share of potential sales for each candidate drug outside Greater China, with a profit-sharing model for IBI363 in the U.S. [2]
信达生物(01801.HK)与武田制药达成全球战略合作，12亿美元首付款+102亿美元里程碑